Ropack Spring Show Guide

Article

Ropack provides contract packaging and manufacturing services for more than 90 U.S., Canadian and European pharmaceutical and consumer healthcare customers. Flexible, responsive and competitive, we focus on reliably accelerating the go-to-market timeline. Our 250,000 square feet of production, warehousing and distribution space includes a 15,000-square-foot, $9M facility for stick-pack packaging of humidity- and temperature-sensitive products. Because of taste-masking and convenience – without compromising integrity – stick-pack is ideal for uni-dose pediatric powders.

E-mail: Paul.dupont@ropack.com

Website: www.ropack.com

Shows attending:

  • BIO - Quebec Pavilion

  • INTERPHEX - booth 1166

  • AAPS Biotech - booth 3649
Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

IL Group Previews Packaging Safety Solutions to be Shown at INTERPHEX

Patrick Lavery
March 14th 2025
Article

The company’s US entity, Iwata Label USA, will exhibit its Vial Protect Pack, Light Protect Pack, and Shrink Tack Label.

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Sun Pharma Agrees to Acquire Checkpoint Therapeutics

Patrick Lavery
March 12th 2025
Article

The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves First Generics of Rivaroxaban Tablets

Patrick Lavery
March 12th 2025
Article

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

New Almac Pharma Services Commercial Manufacturing Facility Opens in Northern Ireland

Patrick Lavery
March 11th 2025
Article

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.